#mirm

Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals Enthorin Therapeutics announced that licensing partner Mirum Pharmaceuticals (NASDAQ: MIRM) initiated the BLOOM Phase 2 clinical study of MRM-3379 (formerly ENT-3379) in Fragile X syndrome in December. MRM-3379 is described as an orally available, highly brain-penetrant, selective PDE4D inhibitor designed to enhance cAMP signaling. The compound was discovered at Dart Neuroscience and advanced through Phase 1; preclinical data in an FMR1 knockout mouse reportedly showed improved cognition and reduced behavioral deficits. Enthorin acknowledged the clinical and scientific teams involved in the decade-long research and development leading to this patient-trial milestone.

2 months ago

#MIRM Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals

www.stocktitan.net/news/MIRM/enthorin-thera...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

2 months ago

#TTD #FOXA #FOX #MIRM #NMAX #87c18a66-f4e3-4c93-9073-38afdc82df31 #investing #Technology #and #Telecom

Origin | Interest | Match

0 0 0 0

Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX Mirum Pharmaceuticals (Nasdaq: MIRM) entered a subscription agreement with entities associated with TCGX for a private placement of 1,000,000 common shares at $68.48 per share, raising approximately $68.5 million in gross proceeds.Combined with a previously announced $200 million private placement, the proceeds are intended to fund clinical development and commercial activities related to the proposed acquisition of Bluejay Therapeutics. Both private placements are expected to close concurrently with the proposed Bluejay acquisition in Q1 2026, subject to regulatory approval and customary closing conditions. The shares are being sold in a private transaction and are not registered under the Securities Act; Mirum and the investors executed registration rights that will become effective at closing.

2 months ago

#MIRM Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX

www.stocktitan.net/news/MIRM/mirum-pharmace...

0 0 0 0

MarketTwits

@markettwits.bsky.social

3 months ago

Mirum Pharma to buy Bluejay Therapeutics for up to $820 million

#MIRM = -2%

0 0 0 0

@prismmarketview.bsky.social

3 months ago

#MIRM Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

www.stocktitan.net/news/MIRM/mirum-pharmace...

0 0 0 0

PRISM MarketView

3 months ago

Mirum Begins Phase 2 Trial of MRM-3379 in Fragile X Syndrome Mirum Pharmaceuticals (NASDAQ: MIRM) has enrolled the first patient in its BLOOM Phase 2 study evaluating MRM-3379 for Fragile X syndrome (FXS), marking a meani

(NASDAQ: #MIRM)
#MirumPharmaceuticals has begun the Phase 2 BLOOM trial of MRM-3379, an oral PDE4D inhibitor, in males with Fragile X syndrome, aiming to improve cognition, behavior, and daily function where no approved therapies currently exist. The 12-week study
prismmarketview.com/mirum-begins...

0 0 0 0

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome Mirum Pharmaceuticals (Nasdaq: MIRM) announced first patient enrollment in the BLOOM Phase 2 study of oral MRM-3379 for Fragile X syndrome (FXS).The randomized trial will evaluate safety, tolerability, and potential clinical benefit in males with a confirmed FMR1 mutation. Top-line data are expected in 2027. The company noted preclinical cognitive and behavioral improvements and favorable tolerability in healthy volunteers. Interested participants can find the study under NCT07209462 on clinicaltrials.gov.

3 months ago

#MIRM Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

www.stocktitan.net/news/MIRM/mirum-pharmace...

0 0 0 0

4 months ago

#MIRM Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/MIRM/mirum-pharmace...

0 0 0 0

雨井

@amtyasan.bsky.social

6 months ago

⚠ #mirm のネタバレ⚠
🫀破りのダーリン！！
【タグミスしたので再投稿】

1 0 0 0

Mirum Crushes Q2 Earnings: Revenue Jumps 64%, LIVMARLI Sales Surge 87%, 2025 Guidance Raised Q2 results show dramatic growth with LIVMARLI sales up 87%. Learn about raised revenue guidance and three major clinical milestones ahead. Get full analysis.

7 months ago

#MIRM Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/MIRM/mirum-pharmace...

0 0 0 0

7 months ago

#mirm
#Opera-san
#fanart
#digitalart

1 0 0 0

9 months ago

#fanart
#mirm
#kalego
#Opera
#kalope

1 0 0 0

9 months ago

Los días de lluvia volvieron
#kalope
#mirm
#fanart
#digitalart

0 0 0 0

Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL Mirum Pharmaceuticals presented promising 28-week data from its Phase 2b VANTAGE study evaluating volixibat for cholestatic pruritus in primary biliary cholangitis (PBC) patients at EASL. The study showed statistically significant improvements in pruritus (itching) and numeric improvements in fatigue, the two most burdensome PBC symptoms.Key findings include:70% of volixibat-treated patients achieved ≥50% reduction in serum bile acidsStatistically significant 3.78-point reduction in ItchRO from baseline in the combined dose groupBoth 20mg and 80mg BID doses showed similar efficacyImprovements in quality of life measures and reductions in IL-31 inflammatory biomarkerThe most common adverse event was mild to moderate diarrhea (77%). Based on similar efficacy and safety results, the 20mg BID dose was selected for the confirmatory portion of the VANTAGE study.

10 months ago

#MIRM Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL

www.stocktitan.net/news/MIRM/volixibat-data...

0 0 0 0

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Mirum Pharmaceuticals (MIRM) reported strong Q1 2025 financial results with total revenue of $111.6 million, a significant increase from $69.2 million in Q1 2024. The company raised its 2025 revenue guidance to $435-450 million. LIVMARLI net product sales reached $73.2 million (71% YoY growth), while Bile Acid Medicines contributed $38.4 million (47% YoY growth). Key achievements include FDA approval of LIVMARLI's oral tablet formulation, Japanese approval for ALGS and PFIC, and CTEXLI approval in the US. The VISTAS study for volixibat in PSC is expected to complete enrollment in Q3 2025. Mirum maintains a strong financial position with $298.6 million in cash and investments as of March 31, 2025.

10 months ago

#MIRM Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/MIRM/mirum-pharmace...

0 0 0 0

InsiderFinance

@insiderfinance.com

10 months ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#HTZ, #SGMO, #MIRM, #ROOT, #LRN

#OptionFlow #OptionsTrading #Trading

0 0 0 0

InsiderFinance

@insiderfinance.com

10 months ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #MSTR 74% OTM
2. #HTZ 51% OTM
3. #SGMO 29% OTM
4. #MIRM 29% OTM
5. #ROOT 27% OTM

#OptionFlow #OptionsTrading #Trading

1 1 0 0

FDA Green Lights Game-Changing Tablet Version of Rare Liver Disease Drug LIVMARLI New tablet formulation offers convenient dosing option for ALGS and PFIC patients. Mirum expands treatment flexibility with June commercial launch. See market impact.

11 months ago

#MIRM Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

www.stocktitan.net/news/MIRM/mirum-s-livmar...

0 0 0 0

11 months ago

Just a cool big brother~ 🙌

mirm COS 魔入間
📷 by KNTP Radish

#mirm #魔入間 #mairuma #魔入りました入間くん #アンドロmジャズ #mairimashitairumakun #andromjazz

4 1 1 0

#mirm
#fanart
#digitalart
#mairuma
#kalope

11 months ago

1 1 0 0

Rep. Rheingans (MI HD47)

@reprheingans.bsky.social

11 months ago

📚 March is Reading Month! We talked about how kids can be leaders, like Autumn Peltier, who is an Anishinaabe water peotector from the north side of the Great Lakes, and learned from her great aunt, known as Grandma Josephine, how to protect the #nibi (water). #MiRM #AnnArbor #A2schools

1 1 0 0

1 year ago

It's almost Ameri's bday 🧡🧡

📷 Pamukii
Edited: Jun

#mirm #魔入間 #魔入りました入間くん #アザゼルアメリ #azazelameri

2 0 0 0

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update Mirum Pharmaceuticals (NASDAQ: MIRM) reported strong financial results for Q4 and full-year 2024, with total net product sales reaching $336.4 million, up from $178.9 million in 2023. The company provided guidance for 2025, expecting global net product sales of $420-435 million.LIVMARLI sales contributed $213.3 million in 2024, while Bile Acid Medicines generated $123.1 million. The global LIVMARLI business expanded to 30 countries, including successful launches in major European markets.Key pipeline developments include expected completion of the VISTAS study enrollment for volixibat in PSC during H2 2025, with topline data in 2026. The company reported $292.8 million in cash and investments as of December 31, 2024, compared to $286.3 million at the end of 2023.

1 year ago

#MIRM Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/MIRM/mirum-pharmace...

0 0 0 0

Medical Milestone: First Treatment for CTX Patients Shows 20x Better Results Than Placebo Groundbreaking FDA approval grants Mirum exclusive rights to treat CTX. Phase 3 study demonstrates 20-fold superiority over placebo in reducing toxic bile alcohols.

1 year ago

#MIRM Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

www.stocktitan.net/news/MIRM/mirum-s-ctexli...

0 0 0 0

1 year ago

💙🎀 𝐻𝒶𝓅𝓅𝓎 𝒱𝒶𝓁𝑒𝓃𝓉𝒾𝓃𝑒'𝓈 𝒟𝒶𝓎 🎀🧡
魔入りました! 入間くん COS

Ameri🧡: me
Iruma💙: Gunn Marano
📷: New
Retoucher: @sleeepingpill.bsky.social

#mirm #魔入間 #魔入りました入間くん #mairuma #イルメリ #IruMeri

1 1 0 0

1 year ago

魔入間コス
mirm

Miss my Ameri~~? 🧡🧡
📷 Pamukii
Edited by @sleeepingpill.bsky.social

#mirm #魔入間 #魔入りました入間くん #アザゼルアメリ

5 2 0 0

Mirum Pharmaceuticals Surpasses 2024 Sales Guidance, Projects Strong 2025 Growth to $435M Mirum reports $336M in 2024 net product sales, led by LIVMARLI's $213M contribution. Company forecasts 30% growth in 2025 with expanded global market presence and robust pipeline progress.

1 year ago

#MIRM Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

www.stocktitan.net/news/MIRM/mirum-pharmace...

0 0 0 0